- Viral respiratory infections treatment encompasses antiviral drugs, immunomodulators, and supportive therapies designed to combat infections such as influenza, respiratory syncytial virus (RSV), rhinovirus, and coronaviruses, which continue to pose significant public health challenges globally, especially among vulnerable populations including children, the elderly, and immunocompromised individuals
- The rising prevalence of viral respiratory infections, seasonal outbreaks, and the emergence of novel pathogens are key drivers accelerating demand for effective treatment options, further supported by increasing awareness, early diagnosis, and improvements in healthcare access
- North America dominated the viral respiratory infections treatment market with the largest revenue share of 38.3% in 2024, owing to robust healthcare infrastructure, high healthcare spending, widespread diagnostic capabilities, and proactive government initiatives to stockpile antiviral medications and vaccines
- Asia-Pacific is expected to be the fastest growing region in the viral respiratory infections treatment market during the forecast period due to a high burden of respiratory infections, growing healthcare investments, and increasing access to antiviral therapies
- The antiviral medications segment dominated the viral respiratory infections treatment market with a market share of 47% in 2024, propelled by the development and approval of targeted therapies for influenza and RSV, as well as strategic partnerships between pharmaceutical firms and public health agencies to expand treatment access
